Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide

[1]  F. Labrie,et al.  Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat , 1989, Breast Cancer Research and Treatment.

[2]  B. Marchetti,et al.  Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors , 1988, Breast Cancer Research and Treatment.

[3]  F. Labrie,et al.  Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line , 1988, Breast Cancer Research and Treatment.

[4]  E. Angerer,et al.  Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours , 2005, Journal of Cancer Research and Clinical Oncology.

[5]  E. Eisenhauer,et al.  Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study , 1988, Investigational New Drugs.

[6]  G. Schaison,et al.  The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. , 1994, Clinical endocrinology.

[7]  Jacques Young,et al.  The impact of a pure anti‐androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism , 1993 .

[8]  A. Pizzini,et al.  The antiandrogen flutamide inhibits growth of mcf-7 human breast-cancer cell-line. , 1993, International journal of oncology.

[9]  M. Soloway,et al.  Antiandrogenic agents as monotherapy in advanced prostatic carcinoma , 1993, Cancer.

[10]  F. Daneshgari,et al.  Endocrine therapy of advanced carcinoma of the prostate , 1993, Cancer.

[11]  D. Bernasconi,et al.  Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T) , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  M. Dowsett,et al.  Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer. , 1991, British Journal of Cancer.

[13]  R. N. Brogden,et al.  Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. , 1991, Drugs & aging.

[14]  F. Labrie,et al.  Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. , 1990, Clinical and investigative medicine. Medecine clinique et experimentale.

[15]  D. Brann,et al.  Similarities and differences in progesterone and androgens in modulation of LH, FSH and PRL release: unexpected properties of flutamide. , 1990, Journal of steroid biochemistry.

[16]  M. Levell,et al.  SUPPRESSION OF PLASMA ANDROGENS BY THE ANTIANDROGEN FLUTAMIDE IN PROSTATIC CANCER PATIENTS TREATED WITH ZOLADEX, A GnRH ANALOGUE , 1990, Clinical endocrinology.

[17]  R. Neri.  Pharmacology and pharmacokinetics of flutamide. , 1989, Urology.

[18]  R. N. Brogden,et al.  Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. , 1989, Drugs.

[19]  M. Dumont,et al.  Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. , 1989, Endocrinology.

[20]  E. Radwanski,et al.  Single and Multiple Dose Pharmacokinetic Evaluation of Flutamide in Normal Geriatric Volunteers , 1989, Journal of clinical pharmacology.

[21]  E. Martino,et al.  The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer , 1988, Journal of endocrinological investigation.

[22]  N. Niederle,et al.  Advanced male breast cancer treatment with the LH‐RH analogue buserelin alone or in combination with the antiandrogen flutamide , 1988, Cancer.

[23]  M. Zambetti,et al.  Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer. , 1988, European journal of cancer & clinical oncology.

[24]  H. Tucker,et al.  Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. , 1988, Journal of medicinal chemistry.

[25]  T. Zhao,et al.  A Phase II Clinical Trial of Flutamide in the Treatment of Advanced Breast Cancer , 1988, Tumori.

[26]  S. Robinson,et al.  Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. , 1987, Cancer research.

[27]  M. Massobrio,et al.  Breast duct fluid dehydroepiandrosterone sulphate in fibrocystic disease. , 1987, European journal of cancer & clinical oncology.

[28]  M. Levell,et al.  Inhibition of rat testicular 17 alpha-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro. , 1987, Journal of steroid biochemistry.

[29]  M. E. El Etreby,et al.  Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats , 1988, The Prostate.

[30]  M. Brentani,et al.  Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: A multivariate analysis approach , 1986, International journal of cancer.

[31]  C. Benz,et al.  Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. , 1986, Cancer research.

[32]  J. Simard,et al.  Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues , 1986, Molecular and Cellular Endocrinology.

[33]  P. Poyet,et al.  Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate , 1985, Molecular and Cellular Endocrinology.

[34]  W. Miller,et al.  Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. , 1985, European journal of cancer & clinical oncology.

[35]  R. Bryan,et al.  Androgen receptors in breast cancer , 1984, Cancer.

[36]  B. Edwards,et al.  Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. , 1983, Annals of internal medicine.

[37]  J. MacIndoe,et al.  An antiestrogenic action of androgens in human breast cancer cells. , 1981, The Journal of clinical endocrinology and metabolism.

[38]  A. Bélanger,et al.  Characteristics of binding to estrogen, androgen, progestin, and glucocorticoid receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and their hormonal control. , 1980, Cancer research.

[39]  F. Labrie,et al.  Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. , 1978, Journal of steroid biochemistry.

[40]  H. Rochefort,et al.  Androgen effects mediated by estrogen receptor in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. , 1978, Cancer research.

[41]  V. Jordan.  Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. , 1976, European journal of cancer.

[42]  R. Neri,et al.  Biological aspects of antiandrogens. , 1975, Journal of steroid biochemistry.

[43]  R. J. Parsons,et al.  Calusterone (7β,17α-DimethyItestosterone) as Primary and Secondary Therapy of Advanced Breast Cancer , 1973 .

[44]  R. Neri,et al.  A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'trifluoromethylisobutyranilide). , 1972, Endocrinology.

[45]  B. Kennedy.  Fluoxymesterone therapy in advanced breast cancer. , 1958, The New England journal of medicine.